GlassScriptPhysician profile
Suzanne J Friedler
NPI 1326048430
$42,078.22
in general payments reported to CMS, 2019-2025
45 companies · $2,991 in 2025
The $2,991 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,396 · 2020: $7,053 · 2021: $8,482 · 2022: $9,902 · 2023: $5,480 · 2024: $3,774 · 2025: $2,991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $750 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,114.14 |
| Consulting Fee | $750.00 |
| Education | $380.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $13,322.30 | 2019-2025 | Epsolay, Nemluvio, Aklief |
| Incyte Corporation | $6,581.02 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $3,748.99 | 2022-2024 | Vtama |
| Leo Pharma INC. | $1,582.23 | 2019-2025 | Adbry |
| Lilly USA, LLC | $1,554.96 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $1,416.83 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $1,138.24 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $1,121.56 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $1,115.77 | 2019-2023 | Valchlor |
| Janssen Biotech, INC. | $945.27 | 2020-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $833.71 | 2019-2023 | Jublia |
| Pfizer INC. | $787.50 | 2019-2024 | |
| Ucb, INC. | $786.01 | 2020-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $746.23 | 2022-2024 | Sotyktu |
| Biofrontera INC. | $736.66 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Friedler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.